Geode Capital Management LLC Boosts Stake in Hims & Hers Health, Inc. $HIMS

Geode Capital Management LLC increased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 1.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,746,081 shares of the company’s stock after purchasing an additional 71,593 shares during the quarter. Geode Capital Management LLC owned approximately 2.12% of Hims & Hers Health worth $236,622,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Northern Trust Corp raised its holdings in Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after purchasing an additional 397,310 shares in the last quarter. Nuveen LLC bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at $58,403,000. BIT Capital GmbH grew its position in shares of Hims & Hers Health by 7.4% in the 1st quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock worth $48,536,000 after buying an additional 112,949 shares during the period. State of Michigan Retirement System increased its stake in shares of Hims & Hers Health by 84.9% in the 2nd quarter. State of Michigan Retirement System now owns 1,379,100 shares of the company’s stock worth $68,748,000 after acquiring an additional 633,300 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Hims & Hers Health by 5.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,325,567 shares of the company’s stock worth $66,080,000 after acquiring an additional 65,275 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HIMS has been the topic of several research reports. Bank of America boosted their price objective on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research note on Tuesday, November 4th. BTIG Research reissued a “buy” rating and issued a $85.00 price target on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Truist Financial cut their price target on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $45.27.

Hims & Hers Health Trading Up 2.9%

Shares of NYSE HIMS opened at $37.09 on Monday. The firm’s 50 day moving average price is $50.63 and its 200-day moving average price is $51.46. Hims & Hers Health, Inc. has a 52-week low of $19.15 and a 52-week high of $72.98. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The company has a market cap of $8.44 billion, a PE ratio of 68.68, a P/E/G ratio of 7.36 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.Hims & Hers Health’s revenue was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $53.48, for a total transaction of $6,852,231.96. Following the sale, the chief executive officer owned 160,425 shares of the company’s stock, valued at $8,579,529. This trade represents a 44.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 13,749 shares of the business’s stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $694,324.50. Following the transaction, the insider directly owned 297,139 shares of the company’s stock, valued at $15,005,519.50. The trade was a 4.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 584,209 shares of company stock worth $31,837,916. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.